These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 3038001)

  • 1. Antimicrobial activity and spectrum of LY146032, a lipopeptide antibiotic, including susceptibility testing recommendations.
    Jones RN; Barry AL
    Antimicrob Agents Chemother; 1987 Apr; 31(4):625-9. PubMed ID: 3038001
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro activity of LY146032 (daptomycin) against selected aerobic bacteria.
    Jorgensen JH; Maher LA; Redding JS
    Eur J Clin Microbiol; 1987 Feb; 6(1):91-6. PubMed ID: 3032612
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative in vitro activity of LY146032 (daptomycin), a new lipopeptide antimicrobial.
    Hodinka RL; Jack-Wait K; Wannamaker N; Walden TP; Gilligan PH
    Eur J Clin Microbiol; 1987 Feb; 6(1):100-3. PubMed ID: 3032607
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro activity of LY146032 (daptomycin), a new peptolide.
    Ehlert F; Neu HC
    Eur J Clin Microbiol; 1987 Feb; 6(1):84-90. PubMed ID: 3032611
    [TBL] [Abstract][Full Text] [Related]  

  • 5. LY146032: activity and resistance development in vitro.
    Mouton RP; Mulders SL
    J Antimicrob Chemother; 1987 Oct; 20(4):513-7. PubMed ID: 2824427
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative in-vitro activity of LY146032 a new peptolide, with vancomycin and eight other agents against gram-positive organisms.
    Benson CA; Beaudette F; Trenholm G
    J Antimicrob Chemother; 1987 Aug; 20(2):191-6. PubMed ID: 2822645
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative in vitro activity of LY146032 (daptomycin) against gram-positive cocci.
    Machka K; Braveny I
    Eur J Clin Microbiol; 1987 Feb; 6(1):96-9. PubMed ID: 3032613
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In-vitro susceptibility of gram-positive cocci to LY146032 teicoplanin, sodium fusidate, vancomycin, and rifampicin.
    Pohlod DJ; Saravolatz LD; Somerville MM
    J Antimicrob Chemother; 1987 Aug; 20(2):197-202. PubMed ID: 2822646
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro activity of teicoplanin and vancomycin against gram-positive bacteria from human clinical and veterinary sources.
    Jensen KT; Schønheyder H; Pers C; Thomsen VF
    APMIS; 1992 Jun; 100(6):543-52. PubMed ID: 1535201
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro activity of LY146032 against staphylococci, streptococci, and enterococci.
    Fass RJ; Helsel VL
    Antimicrob Agents Chemother; 1986 Nov; 30(5):781-4. PubMed ID: 3026240
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro activity of LY146032 against gram-positive bacteria.
    Silva M; Jacobus NV; Gorbach SL
    Diagn Microbiol Infect Dis; 1988 Feb; 9(2):79-85. PubMed ID: 2838217
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antimicrobial susceptibility of Gram-positive bacterial isolates from the Asia-Pacific region and an in vitro evaluation of the bactericidal activity of daptomycin, vancomycin, and teicoplanin: a SENTRY Program Report (2003-2004).
    Biedenbach DJ; Bell JM; Sader HS; Fritsche TR; Jones RN; Turnidge JD
    Int J Antimicrob Agents; 2007 Aug; 30(2):143-9. PubMed ID: 17531446
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antimicrobial activity of coumermycin and recommendations for disk diffusion tests with 5- and 15-micrograms disks.
    Jones RN; Barry AL
    Diagn Microbiol Infect Dis; 1987 May; 7(1):77-82. PubMed ID: 3691036
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro activity of LY146032, a new lipopeptide antibiotic, against gram-positive cocci.
    Verbist L
    Antimicrob Agents Chemother; 1987 Feb; 31(2):340-2. PubMed ID: 3032099
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In-vitro activity of LY146032 against Staphylococcus aureus and S. epidermidis.
    Coudron PE; Johnston JL; Archer GL
    J Antimicrob Chemother; 1987 Oct; 20(4):505-11. PubMed ID: 2824426
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative in-vitro activity of LY146032 and eight other antibiotics against gram-positive bacteria isolated from children.
    Kline MW; Mason EO; Kaplan SL; Lamberth LB; Johnson GS
    J Antimicrob Chemother; 1987 Aug; 20(2):203-7. PubMed ID: 2822647
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Activity of mersacidin, a novel peptide, compared with that of vancomycin, teicoplanin, and daptomycin.
    Niu WW; Neu HC
    Antimicrob Agents Chemother; 1991 May; 35(5):998-1000. PubMed ID: 1649577
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antimicrobial activity, spectrum, and recommendations for disk diffusion susceptibility testing of ceftibuten (7432-S; SCH 39720), a new orally administered cephalosporin.
    Jones RN; Barry AL
    Antimicrob Agents Chemother; 1988 Oct; 32(10):1576-82. PubMed ID: 3190185
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro activities of daptomycin (LY146032) and paldimycin (U-70,138F) against anaerobic gram-positive bacteria.
    Chow AW; Cheng N
    Antimicrob Agents Chemother; 1988 May; 32(5):788-90. PubMed ID: 2840019
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Comparative in vitro activity of daptomycin against gram-positive microorganisms: SENTRY surveillance program, Spain (2002-2006)].
    Loza E; Morosini MI; Pascual A; Tubau F; Alcalá J; Liñares J; Hernández-Bello JR; Baquero F; Perea E; Martín R; Jones RN; Cantón R;
    Enferm Infecc Microbiol Clin; 2008 Oct; 26(8):489-94. PubMed ID: 19094861
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.